XM does not provide services to residents of the United States of America.
T
T

ThermoFisher

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Thermo Fisher Scientific Authorizes $4 Billion Of Share Repurchases

BRIEF-Thermo Fisher Scientific Authorizes $4 Billion Of Share Repurchases Nov 15 (Reuters) - Thermo Fisher Scientific Inc TMO.N : THERMO FISHER SCIENTIFIC AUTHORIZES $4 BILLION OF SHARE REPURCHASES THERMO FISHER SCIENTIFIC INC - NEW AUTHORIZATION REPLACES EXISTING $1 BILLION REMAINING Source text: ID:nBwbNcwJWa Further company coverage: TMO.N
T

U.S. STOCKS Cencora, Charles River, Howmet Aerospace

BUZZ-U.S. STOCKS ON THE MOVE-Cencora, Charles River, Howmet Aerospace Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes soared to record highs on Wednesday, as Republican Donald Trump won the 2024 U.S. presidential election in a remarkable comeback four years after he was voted out of the White House.
P
U
U
H
L
T
W
H
U

Contract research organizations gain after Trump win

BUZZ-Contract research organizations gain after Trump win ** Shares of contract research organizations up 1% to 3% premarket after Donald Trump is elected U.S. president for a second term ** Thermo Fisher Scientific TMO.N up 2%, Danaher DHR.N up 1.9%, Icon ICLR.O up 1.6% and Waters WAT.N up 2.8% ** "Any potential changes to the Inflation Reduction
T
W

Waters Corp raises annual profit forecast on higher demand for lab equipment

Waters Corp raises annual profit forecast on higher demand for lab equipment Nov 1 (Reuters) - Waters Corp WAT.N raised its annual profit forecast after beating Wall Street estimates for third-quarter profit and revenue on Friday, on improved demand for its products and services used in drug development and research. The lab equipment and software maker expects its 2024 adjusted profit to be between $11.67 and $11.87 per share, compared with its prior forecast of $11.55 to $11.65 per share.
T
W

Bio-Rad Laboratories beats quarterly profit estimates on strong sales in diagnostics unit

Bio-Rad Laboratories beats quarterly profit estimates on strong sales in diagnostics unit Oct 30 (Reuters) - Diagnostics firm Bio-Rad Laboratories BIO.N posted third-quarter profit above Wall Street estimates on Wednesday , helped by a recovery in demand for analytical tools from its biotech clients and steady clinical diagnostics products sales growth.
T

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.